Garo Armen Increases Stake in Agenus Inc. (AGEN)

Garo Armen, the Chairman and CEO of Agenus Inc. (NasdaqCM:AGEN), has increased his stake in the company by purchasing 5,364 shares. This transaction took place on June 26, 2026, at an average price of $3.03 per share, amounting to a total value of $16,252.92. Armen's role as the Principal Financial Officer underscores his significant involvement in the company's operations.

Insider Buying and Selling at Agenus Inc.

Garo Armen has been actively purchasing shares of Agenus Inc. over recent months. On June 12, 2026, he bought 4,925 shares at $3.30 each, following earlier purchases of 4,644 shares at $3.50 on May 29, 2026, and 4,540 shares at $3.58 on May 15, 2026. This series of buys suggests his ongoing commitment to the company.

Other Institutional Activity in Agenus Inc.

Several institutional investors have also been adjusting their positions in Agenus Inc. Vanguard Capital Management LLC opened a new position with 1,440,232 shares valued at approximately $4.81 million. Similarly, Vanguard Portfolio Management LLC initiated a stake with 1,195,109 shares worth about $3.99 million. Meanwhile, Marshall Wace, LLP significantly increased its holdings by 541,403 shares, bringing its total to 688,203 shares valued around $2.30 million. In contrast, BlackRock, Inc. trimmed its position by 12,683 shares, now holding 545,662 shares valued at $1.82 million.

Agenus Inc. Stock Down 59.3%

On Tuesday, shares of Agenus Inc. (NasdaqCM:AGEN) traded near $3.16. The company has a market capitalization of approximately $126.2 million and a P/E ratio of 1.48. The stock's 52-week range spans from a low of $2.71 to a high of $7.34. Currently, its 50-day moving average stands at $3.50, and the 200-day moving average is $3.69. Agenus has a beta of 1.544, indicating higher volatility compared to the market.

Analysts Set New Price Targets

HC Wainwright & Co. has reiterated its buy rating for Agenus Inc., setting a price target of $23. The company has also upgraded its rating earlier, reinforcing its positive outlook. The consensus among analysts suggests a mean target price of $15.50, based on two analyst opinions.

About Agenus Inc.

Agenus Inc. is a biotechnology company based in Lexington, Massachusetts, focusing on developing immunotherapies for cancer and infectious diseases. The company offers a range of products, including the Retrocyte Display platform and QS-21 Stimulon adjuvant. Agenus is involved in several collaborations with major firms like Bristol-Myers Squibb and Merck. Founded in 1994, it operates under various trademarks and continues to advance its clinical-stage pipeline.

Bottom Line

Garo Armen's recent purchase of Agenus shares highlights his confidence in the company's future. With other institutional investors also making significant moves, Agenus remains a focal point for market watchers. As always, it's important to note that insider and institutional activity are backward-looking indicators and may not reflect current or future positions.